Antibacterial activity and clinical effect of balofloxacin in the urological field

T. Takenaka, R. Fujita, T. Watanabe, K. Monden, K. Sakuramoto, T. Hayashi, K. Hata, N. Ono, Y. Nasu, H. Kumon, H. Ohmori, Y. Katayama, M. Tsugawa

Research output: Contribution to journalArticlepeer-review


We studied the antimicrobacterial activity and clinical efficacy of balofloxacin (BLFX), a new quinolone, in the urological field. 1) Antibacterial activity: The MICs of BLFX were measured against 210 clinical isolates of 14 species from urinary tract infections and compared with those of ofloxacin (OFLX) and norfloxacin (NFLX). In general, the antibacterial activity of BLFX was inferior to that of OFLX, but almost equal to that of NFLX. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall efficacy rate was 80.0% (4/5) for chronic complicated UTI. Bacteriologically, eleven of the 12 strains isolated (91.7%) were eradicated. 3)Side effects: No clinical adverse reactions anti no abnormal laboratory findings were observed.

Original languageEnglish
Pages (from-to)324-329
Number of pages6
JournalJapanese Journal of Chemotherapy
Issue numberSUPPL. 5
Publication statusPublished - Dec 1 1995


  • balofloxacin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Antibacterial activity and clinical effect of balofloxacin in the urological field'. Together they form a unique fingerprint.

Cite this